Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (DE:BT3)
FRANKFURT:BT3
Lineage Therap (BT3) Ownership - Who Owns Lineage Therap?
0 Followers
Lineage Therap (BT3) Ownership Overview
0.00% Insiders
0.00% Mutual Funds
30.42% Other Institutional Investors
69.58% Public Companies and
Individual Investors
The ownership structure of Lineage Therap (DE:BT3) stock is a mix of institutional, retail and individual investors. Approximately 30.42% of the company’s stock is owned by Institutional Investors, 0.00% is owned by Insiders and 69.58% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| May 28, 2024 | Brian Culley President & Ceo,director | Bought | $10500 |
| Feb 08, 2024 | Don Bailey Director | Bought | $100001 |
| Feb 08, 2024 | Broadwood Partners Lp Director, >10% Owner | Bought | $7000001 |
| Jan 02, 2024 | Anula Jayasuriya Director | Bought | $10900 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Mar 31, 2024 | Bought | $4750771 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 6,888,942 | Insider | ― | 6,475,605 | |
| 83,420,138 | Insider | ― | 78,414,930 | |
| 631,554 | Insider | ― | 593,661 | |
| 1,109,290 | Insider | ― | 1,042,733 | |
| 34,093,007 | Insider | ― | 32,047,427 | |
| 97,450 | Insider | ― | 91,603 | |
| 893,913 | Insider | ― | 840,278 | |
| 64,100 | Insider | ― | 60,254 | |
| 10,000 | Insider | ― | 9,400 | |
| 87,500 | Insider | ― | 82,250 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 900 | Institution | ― | 918 | |
| 42,175 | Institution | ― | 43,019 | |
| 1,581,471 | Institution | ― | 1,613,100 | |
| 39,978 | Institution | ― | 40,778 | |
| 60,723 | Institution | ― | 61,937 | |
| -12,500 | Institution | ― | -12,750 | |
| 22,133 | Institution | ― | 22,576 | |
| 584 | Institution | ― | 596 | |
| 1,177 | Institution | ― | 1,201 | |
| 7,338,576 | Institution | ― | 7,485,348 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|
FAQ
Who Owns Lineage Cell Therapeutics, Inc. (DE:BT3)?
According to the latest TipRanks data, approximately 30.42% of the company's stock is held by institutional investors, 0.00% is held by insiders, and 69.58% is held by retail investors.
What percentage of Lineage Cell Therapeutics, Inc. (DE:BT3) stock is held by institutional investors?
According to the latest TipRanks data, approximately 30.42% of Lineage Cell Therapeutics, Inc. (DE:BT3) stock is held by institutional investors.
What percentage of Lineage Cell Therapeutics, Inc. (DE:BT3) stock is held by retail investors?
According to the latest TipRanks data, approximately 69.58% of Lineage Cell Therapeutics, Inc. (DE:BT3) stock is held by retail investors.
Who owns the most shares of Lineage Cell Therapeutics, Inc. (DE:BT3)?
Alfred Kingsley owns the most shares of Lineage Cell Therapeutics, Inc. (DE:BT3).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.